文献速递肿瘤 PET/CT

Al18F-PSMA-Q的合成、临床前评价及首次人体研究用于前列腺癌显像

Synthesis, preclinical evaluation, and first-in-human study of Al18F-PSMA-Q for prostate cancer imaging.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2022-04-09

本研究自动合成Al18F-PSMA-Q,在体外和荷瘤小鼠中评估其PSMA靶向性并与18F-DCFPyL比较,随后在8名健康志愿者和20例新诊断前列腺癌患者中行注射后1小时PET/CT显像。结果显示该示踪剂制备产率合格、亲水性高、对PSMA有特异性结合,临床前肿瘤摄取和靶本比高于18F-DCFPyL,患者病灶摄取高且辐射剂量合理,提示其用于前列腺癌显像的潜力。

要点

  • Al18F-PSMA-Q自动化制备,未衰减校正放射化学产率22.0-28.3%,比活度>50 GBq/μmol。
  • 临床前22Rv1肿瘤SUVmax 2.17±0.42、靶肌肉比84.37±31.62,高于18F-DCFPyL的1.79±0.39和13.25±1.65。
  • 20例前列腺癌患者中检出26个肿瘤病灶,原发肿瘤平均SUVmax 19.71±16.52。

核心结论

  • 新型合格PSMA靶向示踪剂Al18F-PSMA-Q制备简便、产率和比活度良好,临床前及初步临床研究显示其在前列腺癌病灶中高特异性摄取、靶本比优异且辐射暴露合理,提示其用于前列腺癌显像的潜力。

研究设计与样本

  • 研究包括临床前体外细胞实验、正常小鼠和荷瘤小鼠的药代动力学、生物分布及Micro-PET显像并与18F-DCFPyL比较,以及8名健康志愿者和20例新诊断前列腺癌患者的初步临床PET/CT显像。
  • 临床试验在中国临床试验注册中心注册(ChiCTR2100053507),于2021年11月23日回顾性注册。

主要发现

  • Al18F-PSMA-Q未衰减校正放射化学产率22.0-28.3%,比活度>50 GBq/μmol,log P为-3.69±0.39,对PSMA的Ki值为17.05±1.14 nM。
  • Al18F-PSMA-Q分布半衰期3.93分钟、消除半衰期14.22分钟,均短于18F-DCFPyL。
  • Micro-PET中Al18F-PSMA-Q可清晰区分22Rv1肿瘤与PC-3肿瘤及背景,22Rv1肿瘤SUVmax 2.17±0.42、靶肌肉比84.37±31.62,均高于18F-DCFPyL的1.79±0.39和13.25±1.65;2-PMPA可显著阻断22Rv1细胞和肿瘤摄取。
  • 20例前列腺癌患者共检出26个肿瘤病灶,原发肿瘤、淋巴结转移、骨转移的平均SUVmax分别为19.71±16.52、5.11、31.30±29.85,肿瘤-肌肉比为44.77±22.29。
  • PSA>10 ng/mL患者肿瘤平均SUVmax显著高于PSA≤10 ng/mL患者(25.97±18.64 vs. 10.33±3.74),Gleason评分≥8患者显著高于<8患者(31.85±22.09 vs. 13.18±11.58)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate the potential of a novel Al18F-labeled PSMA-targeted radiotracer for PCa diagnosis through both preclinical and pilot clinical studies. METHODS: Al18F-PSMA-Q was prepared automatically. The binding affinity to PSMA was evaluated in vitro using the 22Rv1 (PSMA +) and PC-3 (PSMA -) cell lines. Pharmacokinetics evaluation, biodistribution study, Micro-PET imaging of Al18F-PSMA-Q in normal mice and tumor-bearing mice, and a comparison with 18F-DCFPyL were performed. PET/CT imaging was performed on 8 healthy volunteers and 20 newly diagnosed PCa patients at 1 h post-injection (p.i.). The biodistribution in human and preliminary diagnostic efficacy of Al18F-PSMA-Q were evaluated, and the radiation dosimetry was estimated using OLINDA/EXM 2.0 software. RESULT: Qualified Al18F-PSMA-Q was efficiently prepared with a non-decay-corrected radiochemical yield (RCY) of 22.0-28.3%, a specific activity (SA) of > 50 GBq/μmol. The hydrophilicity was comparably high with a log P value of - 3.69 ± 0.39. Al18F-PSMA-Q was found to bind to PSMA specifically with a Ki value of 17.05 ± 1.14 nM. The distribution and elimination half-lives of Al18F-PSMA-Q were 3.93 min and 14.22 min, respectively, which were shorter than those of 18F-DCFPyL. Micro-PET imaging of Al18F-PSMA-Q can clearly differentiate 22Rv1 tumors from PC-3 tumors and background with a high SUVmax of 2.17 ± 0.42 and a tumor-to-muscle ratio of 84.37 ± 31.62, which were higher than those of 18F-DCFPyL (1.79 ± 0.39 and 13.25 ± 1.65). The uptake of Al18F-PSMA-Q in 22Rv1 cells and tumors can be substantially blocked by 2-PMPA. High level accumulation of Al18F-PSMA-Q was observed in organs physiologically expressing PSMA. Twenty-six tumor lesions were detected in 20 PCa patients, and the mean SUVmax values of primary tumors, lymph node metastasis, bone metastases, and tumor-muscle ratios were 19.71 ± 16.52, 5.11, 31.30 ± 29.85, and 44.77 ± 22.29, respectively. The mean SUVmax of tumors in patients with PSA > 10 ng/mL was significantly higher than that in patients with PSA ≤ 10 ng/mL (25.97 ± 18.64 vs. 10.33 ± 3.74). Meanwhile, the mean SUVmax of tumors in patients with a Gleason score ≥ 8 was significantly higher than that in patients with a Gleason score < 8 (31.85 ± 22.09 vs. 13.18 ± 11.58). The kidneys received the highest estimated dose of 0.098 ± 0.006 mGy/MBq, and the effective dose was calculated as 0.0128 ± 0.007 mGy/MBq. CONCLUSION: The novel qualified PSMA-targeted radiotracer Al18F-PSMA-Q was conveniently prepared with favorable yield and SA. The results of preclinical and pilot clinical studies exhibited a high specific uptake in PCa lesions and an excellent tumor-to-background ratio with a reasonable radiation exposure, which indicated the great potential of Al18F-PSMA-Q for PCa imaging. TRIAL REGISTRATION: Chinese Clinical trial registry ChiCTR2100053507, Registered 23 November 2021, retrospectively registered.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Wu Y, Zhang X, Zhou H, et al. Synthesis, preclinical evaluation, and first-in-human study of Al18F-PSMA-Q for prostate cancer imaging. Eur J Nucl Med Mol Imaging. 2022. PMID: 35396969. doi:10.1007/s00259-022-05775-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。